World Congress on Controversies in Ophthalmology 16th Annual Congress 2025

Description

+ Include: 41 Videos (.mp4) + 41 Audios (.mp3) + 41 Subtitles (.vtt) + 41 PDFs, size: 11.25 GB

+ Target Audience: ophthalmologists and retina specialists

+ Sample video: contact me for sample video

+ Information:

1. Overview

The World Congress on Controversies in Ophthalmology 16th Annual Congress 2025 provides a dynamic platform for debating the most pressing clinical issues and evolving treatment paradigms in modern eye care. The program features expert-led discussions and head-to-head debates covering a wide array of subspecialties, including retinal diseases, glaucoma management, neuro-ophthalmology, and the integration of artificial intelligence in ophthalmic practice. Course Date: 2025

2. Learning Objectives

• Evaluate current debates and treatment paradigms in the management of diabetic macular edema (DME), neovascular AMD, and inherited retinal diseases.

• Analyze controversial approaches in glaucoma care, including the choice between medical management, traditional trabeculectomy, and minimally invasive glaucoma surgeries (MIGS).

• Assess the evolving role of artificial intelligence, home monitoring, and sustained drug delivery systems in optimizing ophthalmic patient outcomes.

• Navigate complex decisions in neuro-ophthalmology, such as the management of idiopathic intracranial hypertension, optic neuritis, and giant cell arteritis.

• Formulate evidence-based strategies for surgical interventions, including the management of retinal detachments, macular holes, and symptomatic vitreous floaters.

3. Target Audience

Best for ophthalmologists and retina specialists who want updates on controversial treatments, glaucoma surgeries, and novel AMD therapies.

4. Topics

1. 01 Debate – Multi-Pathway or High Dose Inhibitors Improve DME Biomarkers More Than Previous Treatments

2. 02 Debate – Existing Outcome Measures Are Sufficient to Demonstrate the Efficacy of New Therapies for Inherited Retinal Diseases

3. 03 Debate – Functional Visual Loss is an Organic Disease

4. 04 Debate – Idiopathic Intracranial Hypertension is a Medical, Not Surgical Disease Now

5. 05 Neuro-Ophthalmology – The Efferent Cases

6. 06 The Use of Biosimilars in Uveitis

7. 07 Debate – Prophylactic Laser Retinopexy and Early Pars Plana Vitrectomy (PPV) for Preventing Retinal Detachment (RD) in Acute Retinal Necrosis

8. 08 Debate – HLA-Testing Is Mandatory in the Investigation of Posterior Uveitis

9. 09 Systemic Therapy Is the Best Option to Control Uveitic Macular Edema

10. 10 Debate – Post-Operative Macular Edema May Be Considered and Managed as Uveitis

11. 11 Debate – Inflammatory Choroidal Neovascularization May Be Treated by Anti-VEGFs Alone

12. 12 Debate – Should Glaucoma Be Managed by Comprehensive Ophthalmologists or Glaucoma Specialists

13. 13 Glaucoma Drops Should Be Preservative Free From First Line

14. 14 Tradition or Innovation Trabeculectomy Versus Minimally Invasive Bleb-Based Surgeries

15. 15 Debate – All Acute Optic Neuritis Patients Require High Dose Steroids

16. 16 Debate – Temporal Artery Ultrasound Should Replace Temporal Artery Biopsy in Giant Cell Arteritis

17. 17 Cases of Optic Neuritis

18. 18 Debate – Phaco Alone Is Better Than Phaco Plus MIGS

19. 19 Debate – Clinicians Decisions Are Better Than AI Decisions in Glaucoma

20. 20 Debate – Complement Inhibition for Geographic Atrophy Has More Benefits Than Risk

21. 21 Debate – Artificial Intelligence (AI) Can Predict the Success of Retinal Detachment Surgery

22. 22 Debate – Heavy Silicone Is the Most Beneficial Adjuvant in the Successful Management of a Retinal Detachment With Proliferative Vitreoretinopathy (PV…

23. 23 Debate – Multifocal (MF) or Extended Depth of Focus (EDOF) IOLs Can Be Employed After Successful Repair of a Macula-Off Retinal Detachment

24. 24 Debate – Functional Outcomes Need to Be Used for Assessment of Treatment Effects of Drugs for Non-Neovascular Age-Related Macular Degeneration…

25. 25 Debate – Photobiomodulation Is a Viable Treatment in Non-Neovascular AMD

26. 26 Debate – Steroid Therapy for DME Is Still Relevant in the Era of New Generation Anti-VEGF Agents

27. 27 Will Oral Therapy for NPDR Be Adopted as Primary Approach to Management of NPDR

28. 28 Debate – Novel Topical Steroids Will Become Standard of Care for Initial Therapy in Mild Diabetic Macular Edema

29. 29 Debate – Inverted Flap Technique Is the Best Surgical Approach for Large Recurrent Macular Holes in High Myopes

30. 30 Debate – In the Setting of a Phakic Macula-On Retinal Detachment, With a Superior Retinal Tear, Comparable Successful Anatomic and Visual Outcomes …

31. 31 Debate – Pars Plana Vitrectomy Is Safe and Effective in the Management of Symptomatic Vitreous Floaters

32. 32 Debate – Blocking More Than VEGF-A Can Help in Improving Visual Acuity in Retinal Disease

33. 33 Impact of Residual Fluid on Treatment Outcomes in Neovascular Age-Related Macular Degeneration

34. 34 Simultaneous GA and CNVMNV – Incidence, Characteristics, and Treatments

35. 35 Cataract Surgery and Anti-VEGF Management

36. 36 Expert Guidence for the Use of New Regimens With Extended Injection Visit Intervals

37. 37 Debate – Will Topical Therapy Become the Standard of Care for Either Prevention or Delay of Myopia Progression

38. 38 Debate – Gene Therapy for nAMD Will Be the Preferred Therapy in the Future

39. 39 Debate – Sustained Drug Delivery Has a Potential to Be a Significant Treatment Option for Neovascular AMD and Other Retinal Diseases

40. 40 Debate – New Generation Anti-VEGF Agents Are Specifically Beneficial for Pigment Epithelial Detachment

41. 41 Does Home Monitoring Have the Potential to Improve Patient Outcome in AMD